Discontinued Product

Nafadotride (Cat. No. 1347) has been withdrawn from sale for commercial reasons.
Description: Highly potent, preferential D3 antagonist
Chemical Name: N-[(1-Butyl-2-pyrrolidinyl)methyl]-4-cyano-1-methoxy-2-naphthalenecarboxamide
Purity: ≥98% (HPLC)
Citations (2)
Literature (3)

Biological Activity for Nafadotride

Highly potent, competitive, preferential dopamine D3 receptor antagonist. Ki values are 0.52, 5, and 269 nM for human cloned D3, D2 and D4 receptors respectively. Centrally active upon systemic administration.

Licensing Information

Sold with the permission of INSERM and BIOPROJET

Technical Data for Nafadotride

M. Wt 365.47
Formula C22H27N3O2
Storage Store at -20°C
Purity ≥98% (HPLC)
CAS Number 149649-22-9
PubChem ID 3408722

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets for Nafadotride

Certificate of Analysis / Product Datasheet
Select another batch:

References for Nafadotride

References are publications that support the biological activity of the product.

Audinot et al (1998) A comparative in vitro and in vivo pharmacological characterization of the novel DA D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194. J.Pharmacol.Exp.Ther. 287 187 PMID: 9765337

Richtand et al (2000) The DA D3 receptor antagonist nafadotride inhibits development of locomotor sensitization to amphetamine. Brain Res. 867 239 PMID: 10837819

Sautel et al (1995) Nafadotride, a potent preferential DA D3 receptor antagonist, activates locomotion in rodents. J.Pharmacol.Exp.Ther. 275 1239 PMID: 8531087

View Related Products by Target

View Related Products by Product Action

View all D3 Receptor Antagonists

Keywords: Nafadotride, Nafadotride supplier, potent, preferential, D3, antagonists, Dopamine, Receptors, dopaminergic, 1347, Tocris Bioscience

2 Citations for Nafadotride

Citations are publications that use Tocris products. Selected citations for Nafadotride include:

Brewer et al (2014) DA D3 receptor dysfunction prevents anti-nociceptive effects of mor. in the spinal cord. Front Neural Circuits 8 62 PMID: 24966815

Clemens and Hochman (2004) Conversion of the modulatory actions of DA on spinal reflexes from depression to facilitation in D3 receptor knock-out mice. J Neurosci 24 11337 PMID: 15601940

Reviews for Nafadotride

There are currently no reviews for this product. Be the first to review Nafadotride and earn rewards!

Have you used Nafadotride?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Dopamine Receptors Scientific Review

Dopamine Receptors Scientific Review

Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.

Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.